Log In
Monday 24th October 2016

Lung cancer breakthrough

28th September 2006

28092006_lungcancer1.jpgA new non-small cell lung cancer drug known as AS1404 has increased patients' life expectancy significantly in preliminary trials.

Data from a phase II trial of the drug shows that patients who received AS1404 on top of standard chemotherapy lived an average of 14 months, compared with 8.8 months in patients treated with chemotherapy alone. AS1404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours.

The increase in survival time is one of the largest ever seen in a randomised controlled trial combining a new drug with first-line chemotherapy for lung cancer. These results will support plans for a further phase III study.

The biopharmaceutical company Antisoma took the drug through the trials, conducted with 34 lung cancer patients at hospitals in France, Germany, Australia and New Zealand.  The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand.

Cancer Research UK's drug development team played an integral role in the early development of the drug, taking the drug into early stage clinical trials.

Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016